Izba Adverse Reactions

Summary of the safety profile: In a clinical trial of 3 months duration (N = 442) involving IZBA eye drops as monotherapy, the most common adverse reaction observed was hyperaemia of the eye (ocular or conjunctival) reported in approximately 12 % of the patients.
Tabulated list of adverse reactions: The following adverse reactions were assessed to be related with IZBA eye drops monotherapy and are classified according to the following convention: very common ( ≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000).
Within each frequency grouping in Table 2, adverse reactions are presented in decreasing order of seriousness. (See Table 2.)

Click on icon to see table/diagram/image

The following adverse reactions were assessed to be related with Travoprost 40 μg/ml eye drops, solution (either preserved with benzalkonium chloride or polyquaternium-1) and are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping in Table 3, adverse reactions are presented in decreasing order of seriousness. (See Table 3.)

Click on icon to see table/diagram/image